About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal
Noted This Week
Ipsen Biopharmaceuticals said the FDA approved its irinotecan liposome (Onivyde), combined with a chemotherapy regimen of oxaliplatin, fluorouracil, and leucovorin to treat metastatic pancreatic cancer. The phase III NAPOLI 3 trial compared that regimen, called NALIRIFOX, with nab-paclitaxel plus gemcitabine and demonstrated statistically significant improvements in survival. Median overall survival was 11.1 months and 9.2 months, respectively, and progression-free survival was 7.4 months and 5.6 months, respectively.